From the Departments of Cardiothoracic Anesthesiology.
Quantitative Health Sciences.
Anesth Analg. 2023 Mar 1;136(3):507-517. doi: 10.1213/ANE.0000000000006247. Epub 2022 Nov 4.
Precision medicine aims to change treatment from a "one-size-fits-all" approach to customized therapies based on the individual patient. Applying a precision medicine approach to a heterogeneous condition, such as the cardiopulmonary bypass (CPB)-induced inflammatory response, first requires identification of homogeneous subgroups that correlate with biological markers and postoperative outcomes. As a first step, we derived clinical phenotypes of the CPB-induced inflammatory response by identifying patterns in perioperative clinical variables using machine learning and simulation tools. We then evaluated whether these phenotypes were associated with biological response variables and clinical outcomes.
This single-center, retrospective cohort study used Cleveland Clinic registry data from patients undergoing cardiac surgery with CPB from January 2010 to March 2020. Biomarker data from a subgroup of patients enrolled in a clinical trial were also included. Patients undergoing emergent surgery, off-pump surgery, transplantation, descending thoracoabdominal aortic surgery, and planned ventricular assist device placement were excluded. Preoperative and intraoperative variables of patient baseline characteristics (demographics, comorbidities, and laboratory data) and perioperative data (procedural data, CPB duration, and hemodynamics) were analyzed to derive clinical phenotypes using K-means-based consensus clustering analysis. Proportion of ambiguously clustered was used to assess cluster size and optimal cluster numbers. After clusters were formed, we summarized perioperative profiles, inflammatory biomarkers (eg, interleukin [IL]-6 and IL-8), kidney biomarkers (eg, urine neutrophil gelatinase-associated lipocalin [NGAL] and IL-18), and clinical outcomes (eg, mortality and hospital length of stay). Pairwise standardized difference was reported for all summarized variables.
Of 36,865 eligible cardiac surgery cases, 25,613 met inclusion criteria. Cluster analysis derived 3 clinical phenotypes: α, β, and γ. Phenotype α (n = 6157 [24%]) included older patients with more comorbidities, including heart and kidney failure. Phenotype β (n = 10,572 [41%]) patients were younger and mostly male. Phenotype γ (n = 8884 [35%]) patients were 58% female and had lower body mass index (BMI). Phenotype α patients had worse outcomes, including longer hospital length of stay (mean = 9 days for α versus 6 for both β [absolute standardized difference {ASD} = 1.15] and γ [ASD = 1.08]), more kidney failure, and higher mortality. Inflammatory biomarkers (IL-6 and IL-8) and kidney injury biomarkers (urine NGAL and IL-18) were higher with the α phenotype compared to β and γ immediately after surgery.
Deriving clinical phenotypes that correlate with response biomarkers and outcomes represents an initial step toward a precision medicine approach for the management of CPB-induced inflammatory response and lays the groundwork for future investigation, including an evaluation of the heterogeneity of treatment effect.
精准医学旨在改变以往一刀切的治疗方法,转而根据个体患者的情况提供定制化的治疗方案。将精准医学方法应用于心肺转流术(CPB)引起的炎症反应等异质疾病,首先需要确定与生物标志物和术后结果相关的同质亚组。作为第一步,我们通过使用机器学习和模拟工具识别围手术期临床变量中的模式,得出 CPB 诱导的炎症反应的临床表型。然后,我们评估这些表型是否与生物反应变量和临床结果相关。
本单中心回顾性队列研究使用克利夫兰诊所从 2010 年 1 月至 2020 年 3 月接受 CPB 心脏手术的患者注册数据。还纳入了部分参加临床试验的患者的生物标志物数据。排除急诊手术、非体外循环手术、移植、降胸主动脉腹主动脉手术和计划心室辅助设备植入的患者。使用 K-均值共识聚类分析对患者基线特征(人口统计学、合并症和实验室数据)和围手术期数据(手术过程数据、CPB 持续时间和血液动力学)的术前和术中变量进行分析,以得出临床表型。使用歧义聚类的比例来评估聚类的大小和最佳聚类数量。聚类形成后,我们总结了围手术期特征、炎症生物标志物(如白细胞介素 [IL]-6 和 IL-8)、肾脏生物标志物(如尿中性粒细胞明胶酶相关脂质运载蛋白 [NGAL] 和 IL-18)和临床结果(如死亡率和住院时间)。所有汇总变量均报告了成对标准化差异。
在 36865 例符合条件的心脏手术病例中,有 25613 例符合纳入标准。聚类分析得出 3 种临床表型:α、β和γ。表型α(n=6157[24%])包括年龄较大、合并症较多的患者,包括心脏和肾脏衰竭。表型β(n=10572[41%])患者较年轻,大多数为男性。表型γ(n=8884[35%])患者 58%为女性,体重指数较低。表型α患者的预后较差,包括住院时间延长(α组为 9 天,β组和γ组均为 6 天[绝对标准化差异{ASD}=1.15])、更易发生肾衰竭和死亡率更高。与β和γ表型相比,手术后即刻α表型的炎症生物标志物(IL-6 和 IL-8)和肾脏损伤生物标志物(尿 NGAL 和 IL-18)更高。
确定与反应生物标志物和结果相关的临床表型是实现 CPB 诱导的炎症反应精准医学方法的第一步,为未来的研究奠定了基础,包括评估治疗效果的异质性。